Quick Answer
Apimeds Pharmaceuticals US, Inc. reported R&D Expense of $98.5 thousand for fiscal year 2023.
Apimeds Pharmaceuticals US, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $98.5K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $619.7K | — | -4.9% |
| June 30, 2025 | $651.8K | — | — |
- The most recent figure is from Apimeds Pharmaceuticals US, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: